| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1126/SCIENCE.8153622 |
| P698 | PubMed publication ID | 8153622 |
| P2093 | author name string | Walsh TJ | |
| Georgopapadakou NH | |||
| P2860 | cites work | Cispentacin, a new antifungal antibiotic. I. Production, isolation, physico-chemical properties and structure | Q69271137 |
| Lipid composition and polyene antibiotic resistance of Candida albicans mutants | Q105344654 | ||
| P433 | issue | 5157 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | emerging pathogen | Q108429945 |
| P304 | page(s) | 371-373 | |
| P577 | publication date | 1994-04-01 | |
| P1433 | published in | Science | Q192864 |
| P1476 | title | Human mycoses: drugs and targets for emerging pathogens | |
| P478 | volume | 264 |
| Q41829667 | 3D-QSAR CoMFA study of some Heteroarylpyrroles as Possible Anticandida Agents |
| Q30989527 | A non-polyene antifungal antibiotic from Streptomyces albidoflavus PU 23. |
| Q36588959 | A yeast sterol auxotroph (erg25) is rescued by addition of azole antifungals and reduced levels of heme |
| Q41735664 | Active efflux by multidrug transporters as one of the strategies to evade chemotherapy and novel practical implications of yeast pleiotropic drug resistance |
| Q35138591 | Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice. |
| Q42708452 | Anti-Candida activity of 1-18 fragment of the frog skin peptide esculentin-1b: in vitro and in vivo studies in a Caenorhabditis elegans infection model |
| Q40733878 | Antifungal activities of R-135853, a sordarin derivative, in experimental candidiasis in mice |
| Q28343624 | Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action |
| Q35186269 | Antifungal activity of nonantifungal drugs |
| Q52689642 | Antifungal activity, main active components and mechanism of Curcuma longa extract against Fusarium graminearum. |
| Q34400044 | Antifungal agents: chemotherapeutic targets and immunologic strategies |
| Q33749111 | Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance |
| Q37588637 | Antifungal research strategies aiming for new targets |
| Q34768569 | Antifungals targeted to protein modification: focus on protein N-myristoyltransferase |
| Q33538696 | Antifungals: mechanism of action and resistance, established and novel drugs |
| Q47658014 | Antimicrobial activity of extracts of eastern North American hardwood trees and relation to traditional medicine |
| Q29617908 | Aspergillus fumigatus and aspergillosis |
| Q28741795 | Bacterial-fungal interactions: hyphens between agricultural, clinical, environmental, and food microbiologists |
| Q41735660 | Beta-N-acetylhexosaminidase: a target for the design of antifungal agents. |
| Q30827584 | Candida albicans sterol C-14 reductase, encoded by the ERG24 gene, as a potential antifungal target site |
| Q42540712 | Candidacidal activity of salivary histatins. Identification of a histatin 5-binding protein on Candida albicans |
| Q24676192 | Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents |
| Q92538234 | Cinnamaldehyde, a Promising Natural Preservative Against Aspergillus flavus |
| Q34059049 | Cloning of the late genes in the ergosterol biosynthetic pathway of Saccharomyces cerevisiae--a review |
| Q46196819 | Comparing the sugar profiles and primary structures of alkali-extracted water-soluble polysaccharides in cell wall between the yeast and mycelial phases from Tremella fuciformis |
| Q77420483 | Computer-aided target selection-prioritizing targets for antifungal drug discovery |
| Q34071600 | Concepts in design of comparative clinical trials of antifungal therapy in neutropenic patients |
| Q39093310 | Cutaneous bacterial species from Lithobates catesbeianus can inhibit pathogenic dermatophytes |
| Q39692218 | Deletion of individual mRNA capping genes is unexpectedly not lethal to Candida albicans and results in modified mRNA cap structures |
| Q48628624 | Disposition of aerosolized liposomal amphotericin B. |
| Q33996119 | Divergence in fitness and evolution of drug resistance in experimental populations of Candida albicans |
| Q39474468 | Effect of polygodial on the mitochondrial ATPase of Saccharomyces cerevisiae |
| Q37313642 | Effects of hydrophobicity on the antifungal activity of alpha-helical antimicrobial peptides |
| Q26828993 | Emerging drugs and vaccines for candidemia |
| Q46787613 | F2928-1 and -2, new antifungal antibiotics from Cladobotryum sp. |
| Q34404601 | Fungal infections: a growing threat |
| Q97587581 | Genome-wide piggyBac transposon-based mutagenesis and quantitative insertion-site analysis in haploid Candida species |
| Q33971670 | Heterogeneity of Pneumocystis sterol profiles of samples from different sites in the same pair of lungs suggests coinfection by distinct organism populations |
| Q28369019 | Identification and characterization of novel antimicrobial decapeptides generated by combinatorial chemistry |
| Q105082384 | Impacts of development and global change on the epidemiological environment |
| Q28379527 | In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species |
| Q34106775 | In vitro and in vivo antifungal activities of TAK-456, a novel oral triazole with a broad antifungal spectrum |
| Q28343417 | In vitro antifungal activity and cytotoxicity of a novel membrane-active peptide |
| Q33962613 | In vitro damage of Candida albicans biofilms by chitosan |
| Q39657947 | In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. |
| Q34110440 | In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents. |
| Q36525223 | Increased expression of Candida albicans secretory proteinase, a putative virulence factor, in isolates from human immunodeficiency virus-positive patients |
| Q84932845 | Involvement of FgERG4 in ergosterol biosynthesis, vegetative differentiation and virulence in Fusarium graminearum |
| Q42327001 | Isolation and identification of antimicrobial agent-producing bacterium from Taxus baccata rhizosphere antagonistic against clinically significant microbes |
| Q28138241 | LC/MS applications in drug development |
| Q33604227 | Lipid-based amphotericin B for the treatment of fungal infections |
| Q34621454 | Mechanisms of fungal resistance: an overview |
| Q35105782 | Microbial natural products as a source of antifungals |
| Q37210697 | Microbially-produced peptides having potential application to the prevention of dental caries. |
| Q34617356 | Mode of Selection and Experimental Evolution of Antifungal Drug Resistance in Saccharomyces cerevisiae |
| Q45162537 | Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma |
| Q46396112 | New Benzimidazole-1,2,4-Triazole Hybrid Compounds: Synthesis, Anticandidal Activity and Cytotoxicity Evaluation. |
| Q73975599 | Novel nikkomycin analogues: inhibitors of the fungal cell wall biosynthesis enzyme chitin synthase |
| Q40550395 | Oral Candida: clearance, colonization, or candidiasis? |
| Q44525209 | PdCYP51B, a new putative sterol 14α-demethylase gene of Penicillium digitatum involved in resistance to imazalil and other fungicides inhibiting ergosterol synthesis. |
| Q33979139 | Pentamidine inhibition of group I intron splicing in Candida albicans correlates with growth inhibition |
| Q77925974 | Phaeohyphomycosis in kidney transplant patients |
| Q72888863 | Pharmacist-physician link: keys to effective outcomes management |
| Q37820674 | Pharmacoeconomics of voriconazole in the management of invasive fungal infections |
| Q34034817 | Population genomics of drug resistance in Candida albicans. |
| Q41378036 | Pradimicins: a novel class of broad-spectrum antifungal compounds |
| Q44609586 | Production and partial characterisation of an inducer-dependent novel antifungal compound(s) by Pediococcus acidilactici LAB 5. |
| Q35033873 | Rapid analysis of antibiotic-containing mixtures from fermentation broths by using liquid chromatography-electrospray ionization-mass spectrometry and matrix-assisted laser desorption ionization-time-of-flight-mass spectrometry |
| Q43845653 | Rapid detection of lytic antimicrobial activity against yeast and filamentous fungi |
| Q41108756 | Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients |
| Q40531623 | Resistance to antifungal agents |
| Q34528899 | Salivary histatin 5 and its similarities to the other antimicrobial proteins in human saliva |
| Q41489716 | Selective peptidic and peptidomimetic inhibitors of Candida albicans myristoylCoA: protein N-myristoyltransferase: a new approach to antifungal therapy |
| Q39558473 | Sequencing, disruption, and characterization of the Candida albicans sterol methyltransferase (ERG6) gene: drug susceptibility studies in erg6 mutants |
| Q28369140 | Sordarins: in vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii, and filamentous fungi |
| Q28139991 | Sterol C-methyl transferase from Prototheca wickerhamii mechanism, sterol specificity and inhibition |
| Q43962552 | Sterols in erg mutants of Phycomyces: metabolic pathways and physiological effects |
| Q42727846 | Substituted 2-aminothiophenes: antifungal activities and effect on Microsporum gypseum protein profile |
| Q35127954 | Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors |
| Q30805908 | Synergistic antimicrobial activity of metabolites produced by a nonobligate bacterial predator |
| Q71940843 | Synergy of human neutrophils with fluconazole in killing Candida species |
| Q77957220 | Synthesis of 6(alpha, beta)-aminocholestanols as ergosterol biosynthesis inhibitors |
| Q35953363 | Targeted gene replacement demonstrates that myristoyl-CoA: protein N-myristoyltransferase is essential for viability of Cryptococcus neoformans. |
| Q92035433 | The anti-aflatoxigenic mechanism of cinnamaldehyde in Aspergillus flavus |
| Q54065836 | The comparison of characteristics between membrane-active antifungal peptide and its pseudopeptides. |
| Q31936121 | Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors |
| Q34006967 | Virulence of a phosphoribosylaminoimidazole carboxylase-deficient Candida albicans strain in an immunosuppressed murine model of systemic candidiasis |
| Q37546944 | β-(1,3)-Glucan Unmasking in Some Candida albicans Mutants Correlates with Increases in Cell Wall Surface Roughness and Decreases in Cell Wall Elasticity. |
Search more.